Latest Tenofovir Stories
Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis...
Follow-up study planned to further assess gel's potential as a rectal microbicide to prevent HIV A gel formulation of the antiretroviral drug tenofovir designed specifically for rectal use was found safe and acceptable, according to a Phase I clinical study led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), and presented today at the 19th Conference on Retroviruses and Opportunistic Infections (CROI). The results of the study, which included...
CHICAGO, Jan. 20, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences, Inc. (Nasdaq: GILD), Bristol-Myers Squibb Company (NYSE: BMY), Inhibitex, Inc. (Nasdaq: INHX), Vertex Pharmaceuticals (Nasdaq: VRTX) and Merck (NYSE: MRK). (Logo:...
PITTSBURGH, Dec. 20, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include: Atazanavir Capsule, 300 mg, Ritonavir Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and Lamivudine...
New research from the University of North Carolina at Chapel Hill schools of medicine and pharmacy may help explain the failure of some recent clinical trials of prevention of HIV infection, compared to the success of others that used the same drugs. The study published online December 7, 2011 in the journal Science Translational Medicine, also suggests how to improve the chances for success, even before the research begins. These suggestions are reinforced in an editorial by several of...
VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women – daily use of one of two different ARV tablets or of a vaginal gel – will be dropping the vaginal gel from the study. The decision to discontinue use of the gel, which contains the ARV tenofovir, comes after a routine review of study data concluded that tenofovir gel was not effective in preventing HIV in the women enrolled in the trial....
Product safe but no more effective than placebo A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants. On Nov. 17, an independent data and safety monitoring board (DSMB) recommended that the Vaginal and Oral Interventions to Control the Epidemic (VOICE)...
Studies of Different Dosing Regimens to Continue An independent review of the VOICE study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the Microbicide Trials Network, determined that tenofovir gel was no more effective than placebo gel in preventing HIV. The review found no safety concerns and the VOICE study will continue to evaluate the effectiveness of the oral Truvada tablet in preventing HIV in women. It is unknown at this time why...
• 96-week study in a population of nucleos(t)ide-naïve patients with chronic hepatitis B (CHB) infection • Data presented at the American Association for the Study of Liver Diseases congress in San Francisco San Francisco, CA (PRWEB) November 09, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BEâ€LOWâ„¢ study, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (0.5mg once daily) with BARACLUDE (0.5mg once daily)...
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections. Now, a new study published by Cell Press in the October 20th issue of the journal Cell Host and Microbe...
